Search - tctmd.com

Displaying 241 - 254 of 254

Sort: Relevancy | Date

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Air Pollution Joins List of Leading Causes of Stroke Worldwide

Todd Neale

June 10, 2016

News Daily News

Adherence to Guideline-Based Acute MI Therapies Has Prolonged Impact on Mortality Rates

Michael O'Riordan

May 17, 2016

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

Study Supports Use of Low-Dose Aspirin After Acute MI

Todd Neale

May 28, 2015

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

Jason Kahn

August 05, 2013

News Daily News

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

Jason Kahn

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

News Daily News

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Caitlin E. Cox

December 16, 2012

News Daily News

Since COURAGE, Little Change in Optimal Medical Therapy for Stable PCI Patients

Caitlin E. Cox

May 10, 2011

News Daily News

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Jason Kahn

February 09, 2011

News Daily News

More Than 1 in 10 Patients Discontinue Antiplatelet Therapy Early

L.A. McKeown

January 24, 2011

Advertisement

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Air Pollution Joins List of Leading Causes of Stroke Worldwide

Adherence to Guideline-Based Acute MI Therapies Has Prolonged Impact on Mortality Rates

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Study Supports Use of Low-Dose Aspirin After Acute MI

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Since COURAGE, Little Change in Optimal Medical Therapy for Stable PCI Patients

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

More Than 1 in 10 Patients Discontinue Antiplatelet Therapy Early

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content